Revvity (Revvity) Interest Expense : $-100 Mil (TTM As of Mar. 2024)

View and export this data going back to 1983. Start your Free Trial

What is Revvity Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Revvity's interest expense for the three months ended in Mar. 2024 was $ -24 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-100 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Revvity's Operating Income for the three months ended in Mar. 2024 was $ 44 Mil. Revvity's Interest Expense for the three months ended in Mar. 2024 was $ -24 Mil. Revvity's Interest Coverage for the quarter that ended in Mar. 2024 was 1.81. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Revvity Interest Expense Historical Data

The historical data trend for Revvity's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Interest Expense Chart

Revvity Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-63.63

-49.71

-102.13

-103.96

-98.81

Revvity Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-22.74	-26.01	-25.49	-24.58	-24.40

Revvity Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100 Mil.

Revvity (NYSE:RVTY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Revvity's Interest Expense for the three months ended in Mar. 2024 was $-24 Mil. Its Operating Income for the three months ended in Mar. 2024 was $44 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $3,292 Mil.

Revvity's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	44.116	/	-24.397
	=	1.81

The higher the ratio, the stronger the company's financial strength is.

Revvity (Revvity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

PKN:Germany PKN:Germany

Address

940 Winter Street, Waltham, MA, USA, 02451

Website

https://www.revvity.com

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Executives

Anita Gonzales	officer: Please See Remarks	940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra	officer: Please See Remarks	940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg	officer: See Remarks	940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett	director	C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121